Important for the future would be to establish the efficacy of PCSK9 mAb therapy in those with diabetes (especially in those with significant risk factor burden where risk may be similar to many with established ASCVD) for the primary prevention of ASCVD events; however, it is not clear whether such trials will be done in this population. The gene discussed is PCSK9; the disease is atherosclerosis.